The purpose of this study is to assess Bioequivalence (BE), pharmacokinetics (PK), safety and
tolerability following single oral dose administrations between a Glucophage Extended
Release, Reduced Mass (Glucophage XR RM) manufactured in Merck Jiangsu China (test product)
and that manufactured in Merck Darmstadt Germany (reference product) administered under
fasted and fed conditions.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany